Moneycontrol PRO
LAMF
LAMF

Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

Jump to
  • Prefer Aurobindo, Ajanta Pharma, Torrent Pharma: Gujral

  • Like Strides Arcolab for long term, says Deepak Shenoy

  • Like Sun Pharma, Strides Arcolab: Deepak Shenoy

  • Buy Lupin, Shasun Pharmaceuticals: Sudarshan Sukhani

  • Buy Shasun Pharma, advises Pritesh Mehta

  • Top buzzing midcap stocks to trade on June 1

  • Top buzzing midcap stocks to trade on May 27

  • Buy Shasun Pharmaceuticals: Sudarshan Sukhani

  • See 10% overall growth for Sun-Ranbaxy entity: Surajit Pal

  • Focus on midcap pharma space: Gautam Trivedi

  • Midcap pharma look attractive: Anand Tandon

  • Bull's Eye: Buy Reliance Cap, Ashok Leyland, Shasun Pharma

  • Shasun Pharma may go to Rs 215-220: Ambareesh Baliga

  • Buy Den Networks, Sadbhav Engg, Shasun Pharma: Kunal Bothra

  • Buy Sun Pharma, Cipla: Gopi Suvanam

  • Buy Shasun Pharma, M&M, says Pritesh Mehta

  • Super Six: Top chart picks for November 1

  • Do not buy Tata Steel, prefer Idea Cellular: SP Tulsian

    According SP Tulsian of sptulsian.com, one should not buy Tata Steel. "One may prefer Idea Cellular, which has corrected today," he adds.

  • Exit Shasun Pharmaceuticals, says Parag Doctor

    Parag Doctor, Head - Trading Strategies at Keynote Capital's is of the view that one may exit Shasun Pharmaceuticals in current rally.

  • Shasun Pharma may move to Rs 92: Thununguntla

    Jagannadham Thununguntla, Strategist & Head of Research, SMC Global Securities Limited feels Shasun Pharmaceuticals can move to Rs 92.

  • Buy Dewan Housing, Shasun Pharma, Kalpataru Power: Lancelot

    Lancelot D Cunha of Sharyans Wealth Management recommends to buy Dewan Housing Finance Corporation with a target price of Rs 164.10 and Shasun Pharma with a target price of Rs 55.80.

  • Bull's Eye: Buy UCO Bank, Indiabulls Real, Kalpataru Power

    Aashish Tater of Fortunewizard.com advises buying Siti with a target price of Rs 22 and Dena Bank with a target price of Rs 74.

  • Prefer Dr Reddy, Cipla over Shasun Pharma: Sukhani

    Sudarshan Sukhani, s2analytics.com advises to switch from Shasun Pharmaceuticals to Dr Reddy and Cipla.

  • Avoid Dishman Pharma, says SP Tulsian

    SP Tulsian, sptulsian.com don‘t think that Dishman Pharma can correct below Rs 84-85. He feels the major correction seems to have got factored in. However, he still feels one should not invest in Dishman Pharma even at current levels.

  • Sell IVRCL, HDIL, IFCI: Pankaj Jain

    In CNBC-TV18's popular show Bull's Eye, Pankaj Jain of Sunteck Wealthmax shares trading strategy of the day.

Advisory Alert:

It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347